You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,519,226


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,519,226
Title:VEGF neutralizing prodrugs for the treatment of ocular conditions
Abstract: The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
Inventor(s): Rau; Harald (Dossenheim, DE), Knappe; Thomas (Heidelberg, DE), Laufer; Burkhardt (Dossenheim, DE), Reimann; Romy (Heidelberg, DE), Weisbrod; Samuel (Heidelberg, DE), Sprogoe; Kennett (Palo Alto, CA), Bisek; Nicola (Heidelberg, DE), Stark; Sebastian (Heidelberg, DE), Voigt; Tobias (Bensheim, DE)
Assignee: Ascendis Pharma Opthalmology Division A/S (Hellerup, DK)
Application Number:14/435,350
Patent Claims:1. A method for the treatment of one or more ocular conditions, the method comprising: intraocularly administering, by injecting into the aqueous humor, the vitreous body, or the lens of an eye, a pharmaceutical composition comprising: one or more pharmaceutically acceptable excipient(s); and a VEGF neutralizing carrier-linked prodrug comprising a VEGF neutralizing biologically active moiety covalently and reversibly bound to a reversible prodrug linker moiety, wherein the reversible prodrug linker moiety is attached to a hydrogel carrier moiety, either directly or via a spacer moiety; wherein the step of intraocularly administering comprises two intraocular administrations of the prodrug; and wherein a time period between the two intraocular administrations of the VEGF neutralizing prodrug is at least 10 weeks.

2. The method of claim 1; wherein the carrier of the carrier-linked prodrug is a PEG-based hydrogel.

3. The method of claim 1; wherein the prodrug comprised in the pharmaceutical composition has a concentration of 5 to 200 mg prodrug/ml pharmaceutical composition.

4. The method of claim 1; wherein the composition comprises 8 to 80 weight percent of VEGF neutralizing biologically active moiety based on the total weight of the prodrug.

5. The method of claim 1; wherein the injection is carried out with an injection volume ranging from 10 to 200 .mu.l per injection.

6. The method of claim 1; wherein the VEGF neutralizing prodrug comprises in bound form at least one biologically active moiety selected from the group of drugs consisting of: antisense RNA, antisense DNA, ribozymes, and RNAi molecules targeting a VEGF nucleic acid; anti-VEGF aptamers, anti-VEGF antibodies, anti-VEGF antibody fragments, DARPins, and soluble VEGF receptor decoys that prevent binding of a VEGF to its cognate receptor; antisense, ribozymes, and RNAi molecules targeting a cognate VEGF receptor (VEGFR) nucleic acid; anti-VEGFR aptamers and anti-VEGFR antibodies that bind to a cognate VEGFR receptor; anti-VEGFR antibody fragments that bind to a cognate VEGFR receptor; and VEGFR tyrosine kinase inhibitors.

7. The method of claim 1; wherein the VEGF neutralizing prodrug comprises in bound form at least one biologically active moiety selected from the group consisting of ranibizumab, bevacizumab, pegaptanib, aflibercept, MP0112, KH902, ESBA1008, AL 39324, ALG-1001, and bevasiranib.

8. The method of claim 1; wherein the VEGF neutralizing prodrug comprises in bound form ranibizumab.

9. The method of claim 1; wherein the VEGF neutralizing prodrug comprises a moiety of formula (F-i): ##STR00148## wherein: D is ranibizumab; the dashed line indicates attachment to the carrier or to the optional spacer moiety; X.sup.1 is C or S(O); X.sup.2 is C(R.sup.7, R.sup.7a) or C(R.sup.7, R.sup.7a)--C(R.sup.8, R.sup.8a); R.sup.1, R.sup.1a, R.sup.2, R.sup.2a, R.sup.3, R.sup.3a, R.sup.7, R.sup.7a, R.sup.8, and R.sup.8a are independently selected from the group consisting of H and C.sub.1-4 alkyl; optionally, one or more of the pair(s) R.sup.1a/R.sup.4a, R.sup.1a/R.sup.5a, R.sup.4a/R.sup.5a, R.sup.4a/R.sup.5a, R.sup.7a/R.sup.8a form a chemical bond; optionally, one or more of the pair(s) R.sup.1/R.sup.1a, R.sup.2/R.sup.2a, R.sup.4/R.sup.4a, R.sup.5/R.sup.5a, R.sup.7/R.sup.7a, R.sup.8/R.sup.8a are joined together with the atom to which they are attached to form a C.sub.3-7 cycloalkyl or a 4-membered to 7-membered heterocyclyl; optionally, one or more of the pair(s) R.sup.1/R.sup.4, R.sup.1/R.sup.5, R.sup.1/R.sup.6, R.sup.4/R.sup.5, R.sup.7/R.sup.8, R.sup.2/R.sup.3 are joined together with the atoms to which they are attached to form a ring A; optionally, R.sup.3/R.sup.3a are joined together with the nitrogen atom to which they are attached to form a 4-membered to 7-membered heterocycle; A is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C.sub.3-10 cycloalkyl, 4-membered to 7-membered heterocyclyl, and 8-membered to 11-membered heterobicyclyl; and optionally, the moiety of formula (F-i) is further substituted, provided that the hydrogel marked with the asterisk in formula (F-i) is not replaced by a substituent, and that R.sup.3 and R.sup.3a are independently of each other H or are connected to N through an SP.sup.3-hybridized carbon atom.

10. The method of claim 9; wherein X.sup.1 is C.

11. The method of claim 9; wherein the VEGF neutralizing prodrug comprises a moiety of formula (f-ii): ##STR00149## wherein: the dashed line indicates attachment to the carrier; R.sup.1, R.sup.1a, R.sup.2, R.sup.2a, R.sup.3, R.sup.3a, X.sup.2, and D are used as defined in claim 9; R.sup.10 is selected from H and C.sub.1-6 alkyl; and SP.sup.9 is a further spacer moiety, which together with the moiety --NR.sup.10C(O)-- forms the optional spacer moiety; and wherein the moiety of formula (F-ii) is optionally further substituted, provided that the hydrogel marked with the asterisk in formula (F-ii) is not replaced by a substituent and that R.sup.3 and R.sup.3a are independently of each other H or are connected to N through an SP.sup.3-hybridized carbon atom.

12. The method of claim 9; wherein R.sup.1 and R.sup.1a are both H.

13. The method of claim 9; wherein the VEGF neutralizing prodrug comprises a moiety of formula (F-iiia) or (F-iiib): ##STR00150## ##STR00151## wherein: the dashed line indicates attachment to the carrier; R.sup.2, R.sup.2a, R.sup.3, R.sup.3a, R.sup.7, R.sup.7a, R.sup.8, R.sup.8a, X.sup.2, and D are used as defined in claim 9; and R.sup.10 is selected from H and C.sub.1-6 alkyl; and SP.sup.9 is a further spacer moiety, which together with the moiety --NR.sup.10C(O)-- forms the optional spacer moiety; and wherein the moiety of formula (F-iiia) or (F-iiib) is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (F-iiia) and (F-iiib) is not replaced by a substituent, and that R.sup.3 and R.sup.3a are independently of each other H or are connected to N through an SP.sup.3-hybridized carbon atom.

14. The method of claim 9; wherein the VEGF neutralizing prodrug comprises a moiety of formula (F-iva) or (F-ivb): ##STR00152## ##STR00153## wherein: the dashed line indicates attachment to the carrier; R.sup.3 and R.sup.3a are used as defined in claim 9; R.sup.10b is C.sub.1-6 alkyl; and SP.sup.0 is a further spacer moiety, which together with the moiety --NHC(O)-- or --NR.sup.10C(O)-- forms the optional spacer moiety; and wherein the moiety of formula (F-iva) or (F-ivb) is optionally further substituted, provided that the hydrogen marked with the asterisk is not replaced by a substituent and that R.sup.3 and R.sup.3a are independently of each other H or are connected to N through an SP.sup.3-hybridized carbon atom.

15. The method of claim 9; wherein: R.sup.3 is H; and R.sup.3a is methyl.

16. The method of claim 9; wherein R.sup.3 and R.sup.3a of are both H.

17. The method of claim 1; wherein the ocular condition is a disease characterized by ocular neovascularization.

18. The method of claim 17; wherein the disease characterized by ocular neovascularization is an ocular disease selected from the group consisting of optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, corneal neovascularization, vitreal neovascularization, glaucoma, pannus, pterygium, macular edema, macular degeneration, age-related macular degeneration, diabetic retinopathy, diabetic retinal ischemia, diabetic macular edema, vascular retinopathy, retinal degeneration, retrolental fibroplasias, retinoblastoma, retinopathy of prematurity of macular degeneration, corneal graft neovascularization, central retinal vein occlusion, pathological myopia, ocular tumors, uveitis, inflammatory diseases of the eye, and proliferative vitreoretinopathy.

19. The method of claim 1; wherein the pharmaceutical composition further comprises at least one drug in its free form selected from the group consisting of: antisense RNA, antisense DNA, ribozymes, and RNAi molecules targeting a VEGF nucleic acid; anti-VEGF aptamers, anti-VEGF antibodies, anti-VEGF antibody fragments, DARPins, anticalins, lipocalins, and soluble VEGF receptor decoys that prevent binding of a VEGF to its cognate receptor; antisense, ribozymes, and RNAi molecules targeting a cognate VEGF receptor (VEGFR) nucleic acid; anti-VEGFR aptamers and anti-VEGFR antibodies that bind to a cognate VEGFR receptor; anti-VEGFR antibody fragments that bind to a cognate VEGFR receptor; and VEGFR tyrosine kinase inhibitors.

20. The method of claim 1; wherein the pharmaceutical composition further comprises one or more additional prodrug(s), which one or more additional prodrug(s) comprise(s) in bound form at least one biologically active moiety selected from the group consisting of: antisense RNA, antisense DNA, ribozymes, and RNAi molecules targeting a VEGF nucleic acid; anti-VEGF aptamers, anti-VEGF antibodies, anti-VEGF antibody fragments, DARPins, anticalins, lipocalins, and soluble VEGF receptor decoys that prevent binding of a VEGF to its cognate receptor; antisense, ribozymes, and RNAi molecules targeting a cognate VEGF receptor (VEGFR) nucleic acid; anti-VEGFR aptamers and anti-VEGFR antibodies that bind to a cognate VEGFR receptor; anti-VEGFR antibody fragments that bind to a cognate VEGFR receptor; and VEGFR tyrosine kinase inhibitors.

21. The method of claim 1; wherein the carrier of the carrier-linked prodrug is a hyaluronic-acid-based hydrogel.

Details for Patent 10,519,226

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2032-10-11
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 06/30/2006 ⤷  Try a Trial 2032-10-11
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 08/10/2012 ⤷  Try a Trial 2032-10-11
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 10/13/2016 ⤷  Try a Trial 2032-10-11
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 03/20/2018 ⤷  Try a Trial 2032-10-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.